glatiramer acetate 20 mg

DRUG3 trials

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

Relapse-Remitting Multiple SclerosisRelapsing Remitting Multiple Sclerosis

Phase 2

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

CompletedNCT00202982

Teva Branded Pharmaceutical Products R&D, Inc.Relapse-Remitting Multiple Sclerosis

Start: 2003-08-31End: 2005-09-30Updated: 2010-01-14

A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.

CompletedNCT00203073

Teva Branded Pharmaceutical Products R&D, Inc.Relapsing Remitting Multiple Sclerosis

Start: 2003-06-30End: 2005-04-30Updated: 2011-04-14

Phase 3

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

CompletedNCT00337779

Teva Branded Pharmaceutical Products R&D, Inc.Relapsing Remitting Multiple Sclerosis

Start: 2006-08-31End: 2008-10-31Updated: 2011-10-10